{
    "2019-04-17": [
        [
            {
                "time": "2019-04-17",
                "original_text": "华北制药：业绩增七成水分大 研发投入资本化率高",
                "features": {
                    "keywords": [
                        "华北制药",
                        "业绩增长",
                        "研发投入",
                        "资本化率"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "恒瑞医药一季度营收增长29% 净利11.93亿元 董事长孙飘扬未持股",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "营收增长",
                        "净利润",
                        "董事长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "医疗保健：抓住增速快和发展趋势中的医药子行业 荐8股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "医药子行业",
                        "推荐股票"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "应收账款及票据激增六成四 博瑞医药拟冲科创板 对手多为上市公司",
                "features": {
                    "keywords": [
                        "博瑞医药",
                        "应收账款",
                        "科创板",
                        "竞争对手"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "【天风医药】通化东宝：2018年预计将业绩低点，2019年有望恢复快速增长",
                "features": {
                    "keywords": [
                        "通化东宝",
                        "业绩低点",
                        "恢复增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "【天风医药】行业事件点评：《推进养老服务发展的意见》出台，行业逐步规范并迎来新的发展机遇",
                "features": {
                    "keywords": [
                        "养老服务",
                        "政策出台",
                        "行业发展"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "养老"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "券商看好医药板块 多只医药指数估值仍待修复",
                "features": {
                    "keywords": [
                        "券商",
                        "医药板块",
                        "估值修复"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "【天风医药】恒瑞医药：一季报业绩稳定较快增长，潜在重磅产品不断取得研发新进展",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "一季报",
                        "业绩增长",
                        "研发进展"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "【恒瑞医药】19Q1点评：业绩稳健增长，创新龙头步入收获时代",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "业绩增长",
                        "创新龙头"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-17",
                "original_text": "大参考：部分维生素企业停限产 涨价预期逐步发酵",
                "features": {
                    "keywords": [
                        "维生素",
                        "停限产",
                        "涨价预期"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}